These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 15641883)

  • 1. Adjuvant therapeutic effects of galantamine on apathy in a schizophrenia patient.
    Arnold DS; Rosse RB; Dickinson D; Benham R; Deutsch SI; Nelson MW
    J Clin Psychiatry; 2004 Dec; 65(12):1723-4. PubMed ID: 15641883
    [No Abstract]   [Full Text] [Related]  

  • 2. Adjuvant galantamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia.
    Rosse RB; Deutsch SI
    Clin Neuropharmacol; 2002; 25(5):272-5. PubMed ID: 12410061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia.
    Dyer MA; Freudenreich O; Culhane MA; Pachas GN; Deckersbach T; Murphy E; Goff DC; Evins AE
    Schizophr Res; 2008 Jul; 102(1-3):88-95. PubMed ID: 18325740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Galantamine for the treatment of cognitive impairments in people with schizophrenia.
    Buchanan RW; Conley RR; Dickinson D; Ball MP; Feldman S; Gold JM; McMahon RP
    Am J Psychiatry; 2008 Jan; 165(1):82-9. PubMed ID: 17986678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological aspects of the acetylcholinesterase inhibitor galantamine.
    Ago Y; Koda K; Takuma K; Matsuda T
    J Pharmacol Sci; 2011; 116(1):6-17. PubMed ID: 21498956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of galantamine added to clozapine on cognition of five patients with schizophrenia.
    Bora E; Veznedaroğlu B; Kayahan B
    Clin Neuropharmacol; 2005; 28(3):139-41. PubMed ID: 15965314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacological and clinical profiles of galantamine (Reminyl(®))].
    Nagino K; Shikinami K; Saito T; Harada Y
    Nihon Yakurigaku Zasshi; 2011 Sep; 138(3):122-6. PubMed ID: 21908940
    [No Abstract]   [Full Text] [Related]  

  • 8. [Nicotinic Receptor, galantamine and Alzheimer disease].
    Arroyo G; Aldea M; Fuentealba J; García AG
    Rev Neurol; 2002 Jun 1-15; 34(11):1057-65. PubMed ID: 12134305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on Alzheimer drugs (galantamine).
    Raskind MA
    Neurologist; 2003 Sep; 9(5):235-40. PubMed ID: 12971834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Galantamine for treatment-resistant schizophrenia.
    Allen TB; McEvoy JP
    Am J Psychiatry; 2002 Jul; 159(7):1244-5. PubMed ID: 12091212
    [No Abstract]   [Full Text] [Related]  

  • 11. The new cholinesterase inhibitors for Alzheimer's disease, Part 2: illustrating their mechanisms of action.
    Stahl SM
    J Clin Psychiatry; 2000 Nov; 61(11):813-4. PubMed ID: 11105732
    [No Abstract]   [Full Text] [Related]  

  • 12. Galantamine added to antipsychotic treatment in chronic schizophrenia: cognitive improvement?
    Norén U; Björner A; Sonesson O; Eriksson L
    Schizophr Res; 2006 Jul; 85(1-3):302-4. PubMed ID: 16675200
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial.
    Rockwood K; Mintzer J; Truyen L; Wessel T; Wilkinson D
    J Neurol Neurosurg Psychiatry; 2001 Nov; 71(5):589-95. PubMed ID: 11606667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacological profiles of galantamine: the involvement of muscarinic receptor].
    Matsuda T; Ago Y; Takuma K
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Feb; 32(1):1-8. PubMed ID: 22568120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Galantamine hydrobromide: an agent for Alzheimer's disease.
    Zarotsky V; Sramek JJ; Cutler NR
    Am J Health Syst Pharm; 2003 Mar; 60(5):446-52. PubMed ID: 12635450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mechanisms of action of Alzheimer medications].
    Alhainen K
    Duodecim; 2003; 119(20):1959-66. PubMed ID: 14640001
    [No Abstract]   [Full Text] [Related]  

  • 17. Galantamine may improve attention and speech in schizophrenia.
    Ochoa EL; Clark E
    Hum Psychopharmacol; 2006 Mar; 21(2):127-8. PubMed ID: 16482609
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of CDP-choline and the combination of CDP-choline and galantamine differ in an animal model of schizophrenia: development of a selective alpha7 nicotinic acetylcholine receptor agonist strategy.
    Deutsch SI; Rosse RB; Schwartz BL; Schooler NR; Gaskins BL; Long KD; Mastropaolo J
    Eur Neuropsychopharmacol; 2008 Feb; 18(2):147-51. PubMed ID: 17656074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
    Wilkinson DG; Francis PT; Schwam E; Payne-Parrish J
    Drugs Aging; 2004; 21(7):453-78. PubMed ID: 15132713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacological rationale for treating vascular dementia with galantamine (Reminyl).
    Maelicke A
    Int J Clin Pract Suppl; 2001 May; (120):24-8. PubMed ID: 11406923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.